SCHEMBL3256372

SCHEMBL3256372

NC(=O)C(N)S(=O)(=O)c1ccc(F)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.49
SLC1A2 P43004 1/20 0.49
SLC1A1 P43005 1/20 0.49
SOS1 Q07889 2/20 0.39
KMT2A Q03164 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
CA1 P00915 5/20 0.37
CA2 P00918 5/20 0.37
CA9 Q16790 4/20 0.37
CA12 O43570 2/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
PTGS2 P35354 3/20 0.36
PTGS1 P23219 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27874923 0.80 F2 (0.47) SLC1A3SLC1A2SLC1A1SOS1CA1
SCHEMBL571764 0.73 ALDH1A1 (0.50) SLC1A3SLC1A2SLC1A1KMT2ACA1
SCHEMBL30838118 0.72 VCAM1 (0.57) SLC1A3SLC1A2SLC1A1SOS1KMT2A
SCHEMBL4318681 0.72 VCAM1 (0.57) SLC1A3SLC1A2SLC1A1SOS1KMT2A
SCHEMBL9963190 0.72 KMT2A (0.44) SLC1A3SLC1A2SLC1A1SOS1KMT2A
SCHEMBL31456176 0.71 VCAM1 (0.55) SOS1KMT2ATDP1CA1CA2
SCHEMBL27749595 0.70 CA1 (0.50) CA1CA2CA9CA12CA4
SCHEMBL3253848 0.70 TSHR (0.47) PTGS2PTGS1
SCHEMBL1979458 0.69 TDP1 (0.48) SLC1A3SLC1A2SLC1A1SOS1KMT2A
SCHEMBL301718 0.69 CA2 (0.69) SOS1CA1CA2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 SLC1A3 797/4885SLC1A2 544/4885SLC1A1 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.